Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis

Not yet recruiting

• Conditions: Robotic Surgical Procedures; Right Colon Tumors; Cancer; Laparoscopic Abdominal Surgery

• Registration Number: NCT07029464
• Lead Sponsor: The First Affiliated Hospital of Nanchang University

Brief Summary

This is a retrospective, multicenter cohort study to compare short- and long-term outcomes between robotic and laparoscopic hemicolectomy of right colon cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-05-26
• Status Verified: 2025-06
• Study Start: 2025-06
• Study First Submitted QC: 2025-06-17
• Last Update Submitted: 2025-06-17
• Study First Posted: 2025-06-19
• Last Update Posted: 2025-06-19
• Primary Completion: 2026-05
• Study Completion: 2027-05

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 4000

Inclusion Criteria

• 1.Underwent radical right hemicolectomy by Da Vinci robotic or laparoscopic surgery 2.Postoperative pathology confirmed right colon adenocarcinoma (pT2-T4aNxM0; including cecal adenocarcinoma, ascending colon adenocarcinoma, hepatic flexure colon adenocarcinoma, and proximal transverse colon adenocarcinoma) 3.Complete clinical data and pathological results available

Exclusion Criteria

• 1.Received neoadjuvant therapy prior to surgery 2.History of other malignancies in the past 5 years (except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin) 3.Distant metastases (e.g., liver, lung) or extensive abdominal/pelvic metastases confirmed by contrast-enhanced CT, PET-CT, or intraoperative exploration 4.Comorbid neurological/psychiatric disorders impairing ability to express informed consent 5.Poor systemic condition with contraindications to general anesthesia 6.Severe obesity (BMI >35 kg/m²) 7.Severe widespread abdominal adhesions precluding safe pneumoperitoneum establishment 8.Emergency surgery due to tumor perforation or obstruction 9.Refusal to provide informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
3-year overall survival (OS) rate and 3-year disease-free survival (DFS) rate	（OS）From post-operation until death or the 3-year study endpoint （DFS）From post-operation to tumor recurrence or the 3-year study endpoint

Secondary Outcome Measures

Name	Time	Method
Pain score	On postoperative days 1, 3, and 5	Assessed using the Visual Analog Scale (VAS) on postoperative days 1, 3, and 5
Postoperative hospital stay duration	Up to 30 days
Postoperative complications	From end of surgery to 30 days postoperatively	Surgery-related adverse events within 30 days, graded via the Clavien-Dindo classification system
Postoperative white blood cell (WBC) count	On postoperative days 1, 3, and 5	Measured on postoperative days 1, 3, and 5
Postoperative C-reactive protein (CRP) level	On postoperative days 1, 3, and 5	Measured on postoperative days 1, 3, and 5
Operative time	Periprocedural
Intraoperative blood loss	Periprocedural
Time to first flatus/bowel movement	Periprocedural
Time to liquid diet initiation	Periprocedural
Time to ambulation	Periprocedural